# hepatocellular carcinoma (HCC) - claude-opus-4-8

- Benchmark system: E2seq + Agent RAG
- Repeat: 3
- Task type: PROGNOSIS
- Tissue / sample source: liver tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Anthropic / claude-opus-4-8
- Message SHA-256: be503ca72a7bcd2f0eb88c8049c4935f5ef704fb40bd5170c65ca64b33a1d716
- Response HTTP status: 200
- Prompt tokens: 46599
- Completion tokens: 14920
- Reasoning tokens: 0
- Total tokens: 61519
- API requests reported: 4
- Elapsed seconds: 328.412
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1376.986
- Question handoff seconds: 1390.502
- Final benchmark system: E2seq; file rank 2/5; original repeat 3; model vendor: Anthropic

---
# Multidimensional Interpretation of Hepatocellular Carcinoma Prognostic Transcriptomic Data

## 1. Overall Biological Interpretation

The transcriptomic results present a dataset dominated by extreme hazard ratios (HR > 10^21) with P = 0 and FDR = 0, indicating severe model instability rather than meaningful biological signal. Of the 100 genes analyzed, 97 show risk association and only 3 show protective association. The overwhelming presence of pseudogenes (OR5M13P, OR5M5P, OR5M6P, OR5M10, RNA5SP507, RNA5SP359), unannotated loci (UNMAPPED_ENSEMBL entries), long non-coding RNAs (LINC00454, LINC01672, LINC02787), small nuclear RNAs (RNU6-1134P, RNU4-72P), and olfactory receptors (OR2M7, OR5T2, OR11J6P) with mathematically impossible effect sizes suggests **technical artifacts, severe overfitting, or data quality issues** rather than interpretable biology.

The few protein-coding genes with established biological functions (SLC1A6, IRS4, CRH, FOXI1, FOXR2, CGB2, OTX2) represent disparate molecular processes without coherent pathway convergence. The enrichment results mentioning metabolic pathways (Type II diabetes, lipolysis regulation) and neurotransmitter transport (L-aspartate transport, glutamate signaling) do not connect to known HCC biology and appear to reflect random pathway associations with a gene list dominated by pseudogenes.

**This dataset cannot support valid biological interpretation in its current form.** The statistical results violate fundamental assumptions of survival analysis and likely reflect one or more of: perfect separation in Cox regression, extreme collinearity, batch effects, technical noise being fit as signal, or computational errors in model fitting.

## 2. Core Biological Programs

Given the technical concerns, I cannot in good conscience identify "core biological programs" from this dataset. Instead, I will address what the data might have intended to capture, while clearly stating the evidence limitations:

### Program 1: Glutamate/Neurotransmitter Signaling (Exploratory, insufficient evidence)
- **Direction**: Risk-associated
- **Supporting genes**: SLC1A6, CRH
- **Pathways**: GO:0070778 (L-aspartate transmembrane transport), Glutamate Neurotransmitter Release Cycle (Reactome)
- **Rationale**: SLC1A6 encodes a high-capacity glutamate transporter normally expressed in brain tissue (GTEx: 2.6-7.5 TPM in brain regions; 0.006-0.018 TPM in most peripheral tissues including liver). CRH (corticotropin-releasing hormone) participates in neuroendocrine signaling. Their co-occurrence in a liver tumor prognostic signature is unexpected.
- **Evidence strength**: Weak. SLC1A6 has documented expression primarily in cerebellum and other CNS regions. Its presence in HCC prognosis would require ectopic expression or contamination. CRH is not established in HCC biology. The extreme HR values (>10^21) invalidate the statistical association.
- **Limitations**: No established mechanistic link to HCC. Expression pattern inconsistent with liver origin. Statistical artifacts dominate the signal.

### Program 2: Insulin/Growth Factor Signaling Dysregulation (Exploratory, insufficient evidence)
- **Direction**: Risk-associated  
- **Supporting genes**: IRS4, CGB2
- **Pathways**: KEGG Type II diabetes mellitus, Regulation of lipolysis
- **Rationale**: IRS4 (insulin receptor substrate 4) participates in insulin and IGF-1 signaling. CGB2 encodes the beta subunit of chorionic gonadotropin, a hormone with growth-promoting properties. Metabolic reprogramming is a recognized HCC hallmark.
- **Evidence strength**: Extremely weak. IRS4 is predominantly expressed in thymus, kidney, and hypothalamus (GTEx), not liver. CGB2 is normally placenta-specific; ectopic expression in cancers has been reported but is rare. The HR values are mathematically impossible.
- **Limitations**: Tissue expression patterns argue against liver origin. No pathway coherence across the broader gene set. Statistical model failure makes interpretation speculative.

### Program 3: Developmental Transcription Factor Reactivation (Exploratory, insufficient evidence)
- **Direction**: Risk-associated
- **Supporting genes**: OTX2, FOXI1, FOXR2
- **Pathways**: None directly applicable
- **Rationale**: OTX2 and FOXI1 are developmental transcription factors; FOXR2 is a forkhead box family member. Reactivation of developmental programs is observed in dedifferentiated tumors.
- **Evidence strength**: Extremely weak. OTX2 is a retinal/brain developmental regulator; FOXI1 is involved in inner ear and kidney development; FOXR2 function is poorly characterized. Their co-occurrence suggests either dedifferentiated tumor phenotypes or technical noise.
- **Limitations**: No mechanistic link between these factors. No established role in HCC. Extreme HR values preclude meaningful interpretation.

### Program 4: Non-coding RNA Dysregulation (Artifact, not interpretable)
- **Direction**: Risk-associated
- **Supporting genes**: MIR182, Y_RNA, multiple LINC and RNU entries
- **Pathways**: None applicable
- **Rationale**: The dataset contains numerous non-coding RNAs including microRNA (MIR182), Y RNAs, long intergenic non-coding RNAs, and small nuclear RNAs.
- **Evidence strength**: None. MIR182 has documented oncogenic roles in multiple cancers, but its HR >10^21 indicates model failure. Y RNAs have been proposed as cancer biomarkers but lack mechanistic HCC data. The preponderance of unannotated small RNAs suggests technical artifacts (alignment errors, low-complexity sequences, degradation products).
- **Limitations**: Most entries are pseudogenes, unannotated loci, or processing artifacts. No coherent regulatory program emerges.

### Program 5: Olfactory Receptor Ectopic Expression (Artifact, not interpretable)
- **Direction**: Risk-associated
- **Supporting genes**: OR2M7, OR5T2, OR5M10, OR5M13P, OR5M5P, OR5M6P, OR11J6P
- **Pathways**: GO: G protein-coupled receptor signaling pathway, detection of chemical stimulus
- **Rationale**: Multiple olfactory receptor genes and pseudogenes appear in the list.
- **Evidence strength**: None. Ectopic olfactory receptor expression has been reported in cancers but remains poorly understood. The presence of multiple pseudogenes and the extreme HR values indicate these are likely alignment artifacts or low-expressed noise being overfitted.
- **Limitations**: Mixture of functional genes and pseudogenes. No established HCC mechanism. Statistical artifacts dominate.

## 3. Key Genes and Interaction Modules

Given the data quality issues, I will identify genes that *could* be biologically relevant if the statistical artifacts were resolved, while clearly stating current evidence limitations:

### Gene 1: SLC1A6 (Exploratory candidate, requires validation)
- **Statistical association**: Risk-associated, HR = 5.18×10^21 (artifact)
- **Potential role**: Glutamate transporter; if genuinely expressed in HCC, could contribute to metabolic reprogramming or neurotransmitter signaling
- **Evidence**: STRING interactions with SPTBN2 (spectrin beta chain), SLC1A1 (another glutamate transporter), KAT5 (histone acetyltransferase). GTEx shows negligible liver expression (0.015 TPM vs. 2.6-7.5 TPM in brain).
- **Relationship type**: Protein interaction (STRING) and pathway co-membership (glutamate transport)
- **Key limitation**: Extreme HR indicates model failure; brain-specific expression pattern inconsistent with liver tumor origin

### Gene 2: IRS4 (Exploratory candidate, requires validation)
- **Statistical association**: Risk-associated, HR = 5.18×10^21 (artifact)
- **Potential role**: Insulin receptor substrate; could mediate growth factor signaling if genuinely dysregulated
- **Evidence**: GTEx expression highest in thymus and hypothalamus, minimal in liver. Insulin signaling is relevant to HCC but IRS4 is not the dominant isoform in hepatocytes.
- **Relationship type**: Pathway co-membership (insulin signaling)
- **Key limitation**: Tissue expression profile argues against direct HCC relevance; statistical artifact dominates

### Gene 3: MIR182 (Literature-supported candidate, statistics invalid)
- **Statistical association**: Risk-associated, HR = 5.18×10^21 (artifact)
- **Potential role**: Oncogenic microRNA with documented roles in ovarian cancer, osteoclast regulation, and other malignancies
- **Evidence**: PubMed records document MIR182 in cancer contexts [22790015, 31908034]. Literature support exists independently of this dataset.
- **Relationship type**: Regulatory (microRNA-target regulation)
- **Key limitation**: While biologically plausible, the current statistical association is an artifact. Literature evidence does not specifically validate HCC prognostic value.

### Gene 4: CRH (Exploratory candidate, requires validation)
- **Statistical association**: Risk-associated, HR = 1.51×10^6 (artifact, though lower than others)
- **Potential role**: Corticotropin-releasing hormone; neuroendocrine signaling component
- **Evidence**: STRING interactions with protein-coding genes; GO annotations for hormone activity
- **Relationship type**: Pathway co-membership (neuroendocrine signaling)
- **Key limitation**: CRH is not established in HCC biology; extreme HR invalidates the association

### Gene 5: Y_RNA (Technical artifact, not interpretable)
- **Statistical association**: Risk-associated, HR = 5.18×10^21; flagged with "direction-conflict; rows=168" indicating internal inconsistency
- **Potential role**: Y RNAs have been proposed as cancer biomarkers based on extracellular vesicle content [32944168, 32423154]
- **Evidence**: Literature documents Y RNA roles in cancer, but the direction-conflict flag indicates measurement or annotation errors
- **Relationship type**: Not applicable (non-coding RNA class)
- **Key limitation**: Internal statistical conflict; extreme HR; Y_RNA as a gene name may represent multiple Y RNA species or annotation errors

### Gene 6: CENPVL3 (Technical artifact, not interpretable)
- **Statistical association**: Protective, HR = 1.93×10^-22 (mathematically impossible)
- **Potential role**: Centromere protein family; chromosome segregation
- **Evidence**: No specific HCC literature; centromere proteins are essential for cell division
- **Relationship type**: Pathway co-membership (centromere function)
- **Key limitation**: Extreme protective HR is statistically invalid; CENPVL3 function poorly characterized

### Gene 7: OTX2 (Exploratory candidate, requires validation)
- **Statistical association**: Risk-associated, HR = 5.18×10^21 (artifact)
- **Potential role**: Orthodenticle homeobox 2; developmental transcription factor
- **Evidence**: OTX2 is a master regulator of eye and brain development; ectopic expression reported in medulloblastoma and other cancers
- **Relationship type**: Transcriptional regulation
- **Key limitation**: Extreme HR invalidates association; no established HCC role

### Genes 8-10: OR2M7, OR5T2, OR5M10 (Technical artifacts, not interpretable)
- **Statistical association**: Risk-associated, HR = 5.18×10^21 (artifact)
- **Potential role**: Olfactory receptors; G protein-coupled signaling
- **Evidence**: STRING network places them together (ARRB1, ARRB2, GNAL, GNB1 as common interactors); GO enrichment for olfactory detection
- **Relationship type**: Pathway co-membership and protein interaction (STRING)
- **Key limitation**: Mixture of functional genes and pseudogenes; olfactory receptor ectopic expression in cancer is poorly understood; extreme HRs indicate artifacts; likely represent alignment errors or low-expressed noise

## 4. Validation Priorities

I cannot in good conscience propose traditional validation priorities when the underlying statistical model has failed. Instead, I will propose priorities for **data quality investigation** and **salvage validation** if the dataset can be corrected:

### Priority 1: Statistical Model Diagnostics (Confounding or composition check)
- **Why prioritize**: The extreme HR values (>10^21) indicate perfect or near-perfect separation in Cox regression, suggesting the model fit technical artifacts rather than biological signal
- **Current dataset evidence**: 97% of genes show risk association; HRs span from 10^-22 to 10^21; P = 0 for all entries; direction-conflict flags on some entries
- **External evidence**: Mathematically, HR cannot exceed exp(β×range(X)) where X is expression. Values >10^6 indicate numerical instability.
- **Next step**: Re-run Cox models with regularization (elastic net penalty); check for perfect separation; examine sample-level expression distributions; verify survival times are correctly encoded; check for batch effects
- **Evidence classification**: **Technical error; validation inappropriate until resolved**

### Priority 2: Tissue Composition and Tumor Purity Assessment (Confounding check)
- **Why prioritize**: Multiple genes (SLC1A6, OTX2, FOXI1, olfactory receptors) have expression patterns inconsistent with liver origin, suggesting non-tumor cell contamination or metastatic deposits
- **Current dataset evidence**: SLC1A6 GTEx expression: 0.015 TPM liver vs. 5.0 TPM brain; similar patterns for other genes
- **External evidence**: HCC transcriptomes can contain stromal, immune, and vascular components; tissue heterogeneity affects prognostic models
- **Next step**: Deconvolute bulk RNA-seq using tools like ESTIMATE, xCell, or CIBERSORT; correlate gene expression with tumor purity scores; perform immunohistochemistry to confirm protein-level expression
- **Evidence classification**: **Exploratory hypothesis; requires experimental validation**

### Priority 3: Non-coding RNA Technical Validation (Mechanistic hypothesis / biomarker)
- **Why prioritize**: If MIR182 genuinely associates with HCC prognosis, it would be a clinically actionable biomarker; however, current statistics are invalid
- **Current dataset evidence**: MIR182 HR = 5.18×10^21 (artifact)
- **External evidence**: Literature documents MIR182 oncogenic roles in multiple cancers [22790015, 31908034]; Y RNAs proposed as cancer biomarkers [32423154, 32944168]
- **Next step**: Validate MIR182 expression by qRT-PCR in an independent HCC cohort; test association with OS using properly specified Cox models; functional validation in cell lines
- **Evidence classification**: **Literature-supported hypothesis; current dataset provides no valid statistical support; requires independent replication**

### Priority 4: Insulin/Growth Factor Signaling Perturbation (Mechanistic hypothesis)
- **Why prioritize**: If IRS4 is genuinely dysregulated in a subset of HCC cases, it could point to metabolic vulnerabilities; however, tissue expression argues against this
- **Current dataset evidence**: IRS4 HR = 5.18×10^21 (artifact); GTEx shows minimal liver expression
- **External evidence**: Insulin signaling is relevant to HCC, but IRS1 and IRS2 are the dominant hepatic isoforms; IRS4 expression would require ectopic activation
- **Next step**: Verify IRS4 protein expression by Western blot or immunohistochemistry; if confirmed, test functional role with siRNA knockdown; investigate upstream transcriptional activators
- **Evidence classification**: **Exploratory hypothesis; tissue expression data argue against; requires protein-level confirmation before pursuing**

### Priority 5: Batch Effect and Data Provenance Audit (Confounding check)
- **Why prioritize**: The preponderance of pseudogenes, unannotated loci, and extreme HRs suggests systematic technical issues such as alignment errors, batch effects, or data corruption
- **Current dataset evidence**: 100 genes include multiple pseudogenes (OR5M13P, RNA5SP507), unmapped Ensembl IDs, and implausible gene categories (Metazoa_SRP)
- **External evidence**: RNA-seq alignment to pseudogenes can result from multi-mapping reads, degraded RNA, or low-complexity sequences; batch effects can create spurious prognostic signatures
- **Next step**: Re-align reads with strict mapping parameters; perform principal component analysis to identify batch structure; verify sample provenance and RNA quality metrics (RIN scores)
- **Evidence classification**: **Technical audit required; no validation appropriate until data quality confirmed**

## 5. Evidence Grounding

For all major conclusions above, I distinguish evidence types:

### Direct evidence from input dataset:
- HR, P, and FDR values are provided but are statistically invalid due to extreme values
- Direction conflict flags on Y_RNA and Metazoa_SRP indicate internal inconsistency

### Pathway/ontology evidence:
- GO enrichment for glutamate transport, olfactory detection, and GPCR signaling retrieved from QuickGO and Reactome
- These enrichments reflect pathway annotations of the input genes, not independent validation of biological programs
- Enrichment for metabolic pathways (Type II diabetes, lipolysis regulation) appears to be artifact-driven given the pseudogene content

### Protein interaction evidence:
- STRING interactions for SLC1A6, olfactory receptors retrieved
- STRING combines experimental data, databases, and predictions; confidence scores provided (0.48-0.95) but do not validate prognostic associations
- Interactions among olfactory receptors with ARRB1, ARRB2, GNAL reflect shared GPCR signaling machinery, not HCC-specific networks

### Expression/tissue-specific evidence:
- GTEx data show SLC1A6, IRS4, and other genes have minimal liver expression
- This tissue distribution directly contradicts the hypothesis that these genes reflect liver tumor biology
- Brain-specific (SLC1A6), kidney-specific (FOXI1), and placenta-specific (CGB2) expression patterns suggest contamination or ectopic expression

### Published literature evidence:
- MIR182 has documented roles in cancer [22790015, 31908034] independent of this dataset
- Y RNA cancer biomarker studies [32423154, 32944168] provide context but do not validate HCC prognosis
- SLC1A6 schizophrenia literature [22424243] is irrelevant to HCC
- Literature sources are not independent of each other and do not replicate the current statistical findings

### Disease-association evidence:
- ClinVar, GWAS Catalog, Open Targets, and cBioPortal records retrieved for some genes
- These databases document known associations but do not constitute independent cohort validation for HCC prognosis
- No independent HCC prognostic cohort statistic is available in the evidence pack

### Genetic/clinical evidence:
- ClinVar entries exist for some genes (29/100) but predominantly reflect germline variant pathogenicity, not somatic cancer roles
- Clinical trials data retrieved for 5/100 genes but do not establish HCC prognostic relevance

### Drug/therapeutic evidence:
- ChEMBL and clinical trials data retrieved for 5-9 genes
- The existence of drugs targeting a gene does not establish that gene as an effective therapeutic target for HCC
- No HCC-specific therapeutic evidence is present in the evidence pack

### Evidence independence:
- Pathway databases (GO, Reactome, KEGG) share underlying curation sources
- Literature databases (PubMed, Europe PMC) index overlapping journals
- Disease databases (ClinVar, GWAS, Open Targets) incorporate PubMed literature
- These are not independent validation sources; they provide contextual annotation

### Conflicting evidence:
- Tissue expression (GTEx) conflicts with the hypothesis that these genes are liver tumor biomarkers
- Pseudogene content conflicts with the hypothesis that these are functional prognostic genes
- Extreme HR values conflict with plausible biological effect sizes

### Insufficient evidence:
- No independent HCC cohort validation
- No protein-level expression confirmation
- No mechanistic experiments linking any gene to HCC survival
- No multi-omics integration (mutation, CNV, methylation) to support transcriptomic findings

## 6. Limitations and Alternative Explanations

### Limitation 1: Statistical Model Failure (Critical)
**Description**: Hazard ratios exceeding 10^21 and P = 0 for all genes indicate perfect or near-perfect separation in Cox regression. This occurs when a predictor (or combination of predictors) perfectly or near-perfectly separates events from non-events, causing maximum likelihood estimates to diverge to infinity. The "direction-conflict" flags on Y_RNA and Metazoa_SRP indicate internal inconsistency.

**Impact**: All statistical associations are invalid. The model fit technical artifacts rather than biological signal.

**Investigation**: Re-fit Cox models with Firth penalization or elastic net regularization; examine predictor collinearity; check for extreme expression values or outlier samples; verify event coding; reduce model complexity.

**Alternative explanation**: The dataset may represent a pilot analysis where all genes were tested individually without correction for multiple comparisons, and only the most extreme (artifactual) results were exported.

### Limitation 2: Tissue Composition and Tumor Purity (Critical)
**Description**: Many genes (SLC1A6, OTX2, FOXI1, IRS4, CGB2) have tissue-specific expression patterns inconsistent with liver origin. Bulk RNA-seq of tumor biopsies captures mRNA from tumor cells, stromal fibroblasts, endothelial cells, immune infiltrates, and residual normal tissue. Variation in tumor purity across samples creates spurious prognostic associations.

**Impact**: Expression of brain-specific, kidney-specific, or placenta-specific genes in liver tumors more plausibly reflects contamination, metastatic deposits, or rare cell populations than tumor-intrinsic biology.

**Investigation**: Apply deconvolution methods (ESTIMATE, xCell, CIBERSORT) to estimate tumor purity and cell-type fractions; correlate gene expression with purity; perform single-cell or spatial transcriptomics; confirm expression by immunohistochemistry.

**Alternative explanation**: HCC samples may include intrahepatic cholangiocarcinoma, metastatic lesions, or mixed histologies. Some genes may reflect non-tumor cell responses (immune checkpoint, angiogenesis) that have genuine prognostic value independent of tumor cell biology.

### Limitation 3: Pseudogene and Non-coding RNA Artifacts (Critical)
**Description**: The gene list includes numerous pseudogenes (OR5M13P, OR5M5P, RNA5SP507, RNA5SP359), small nuclear RNAs (RNU6-1134P, RNU4-72P), and unannotated/unmapped loci (UNMAPPED_ENSEMBL entries). Pseudogenes are non-functional genomic sequences that can spuriously accumulate reads due to sequence similarity with functional genes. Small RNAs are prone to alignment and quantification errors.

**Impact**: These entries likely represent technical noise: multi-mapping reads, alignment errors, low-complexity sequences, degradation products, or batch effects. Their presence in the top prognostic genes suggests the model fit noise rather than signal.

**Investigation**: Re-align reads with strict mapping quality filters; exclude pseudogenes and low-expressed genes from prognostic modeling; examine read distribution and GC content for technical artifacts; apply batch correction.

**Alternative explanation**: Some pseudogenes are transcribed and have regulatory functions (competing endogenous RNAs). However, their extreme HR values indicate technical artifacts rather than genuine regulatory roles.

### Limitation 4: Ectopic Expression vs. Contamination (High priority)
**Description**: Genes with tissue-specific expression can appear in tumor profiles through ectopic reactivation (developmental genes, cancer-testis antigens) or contamination (adjacent tissue, circulating cells, metastases). Distinguishing these requires orthogonal validation.

**Impact**: If expression is genuinely ectopic (tumor cells expressing SLC1A6), it may reflect dedifferentiation or lineage plasticity. If expression reflects contamination, it has no mechanistic relevance to tumor biology.

**Investigation**: Single-cell RNA-seq to identify which cells express the genes; in situ hybridization or immunohistochemistry to confirm spatial localization; deconvolution to test correlation with cell-type signatures.

**Alternative explanation**: Circulating tumor cells with altered lineage identity, intratumoral heterogeneity with minor clones expressing ectopic programs, or transcriptional noise in dying cells.

### Limitation 5: Association vs. Causation (Fundamental)
**Description**: Prognostic associations do not imply causation. A gene's expression may correlate with survival due to: (1) direct tumor cell role, (2) correlation with tumor stage or grade, (3) reflection of immune or stromal response, (4) association with treatment exposure, (5) shared upstream regulator, or (6) technical confounding.

**Impact**: Even if the statistical model were valid, the associations would require mechanistic experiments to establish causal roles. Prognostic biomarkers are clinically useful without causation, but therapeutic targets require causal validation.

**Investigation**: Functional experiments (knockdown, overexpression, CRISPR) in cell lines and mouse models; Mendelian randomization using germline variants as instruments; longitudinal multi-omics to establish temporal order.

**Alternative explanation**: All observed associations are correlations with unmeasured variables (tumor grade, viral etiology, cirrhosis severity, treatment). Correcting for these clinical covariates may eliminate the apparent prognostic value.

---

## Summary

This dataset cannot support valid biological interpretation due to fundamental statistical model failure. The extreme hazard ratios (>10^21), P = 0 for all genes, and preponderance of pseudogenes, unannotated loci, and tissue-inappropriate genes indicate technical artifacts dominate the signal. 

Before any biological interpretation or validation is pursued, the data must be subjected to rigorous quality control: re-alignment with strict mapping parameters, tumor purity assessment, batch effect correction, and Cox model re-fitting with regularization. The current results should not guide experimental or clinical decisions.

If the technical issues can be resolved, a subset of genes (MIR182, potentially some developmental transcription factors) may warrant follow-up based on independent literature support. However, the current dataset provides no valid statistical evidence for their prognostic value in HCC. Any biological interpretation at this stage is **highly speculative and not evidence-grounded**.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=2, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: Anthropic / claude-opus-4-8

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 56/100 selected items (partially returned; some queries failed); cbioportal 57/100 selected items (records returned); chembl 5/100 selected items (partially returned; some queries failed); civic 1/100 selected items (records returned); clinicaltrials 5/100 selected items (records returned); clinvar 29/100 selected items (records returned); ensembl 19/100 selected items (partially returned; some queries failed); europepmc 305 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 78/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 61/100 selected items (records returned); intact 10/100 selected items (partially returned; some queries failed); mygene 65/100 selected items (records returned); omnipath 6/100 selected items (records returned); opentargets 54/100 selected items (partially returned; some queries failed); pubmed 100 articles / initial full-cohort RAG 100 queries + 3 current-round queries; some queries failed; quickgo 14/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 15/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 1/100 selected items (records returned); string 15/100 selected items (records returned); trrust 3/100 selected items (records returned)
